This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameButhionine Sulfoximine
Accession NumberDB12870
TypeSmall Molecule
GroupsInvestigational
Description

Buthionine Sulfoximine has been used in trials studying the treatment of Neuroblastoma and Melanoma (Skin).

Structure
Thumb
SynonymsNot Available
External IDs Not Available
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIILW4108Q0BV
CAS number5072-26-4
WeightAverage: 222.3
Monoisotopic: 222.103813622
Chemical FormulaC8H18N2O3S
InChI KeyKJQFBVYMGADDTQ-UHFFFAOYSA-N
InChI
InChI=1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)
IUPAC Name
2-amino-4-[butyl(imino)oxo-lambda6-sulfanyl]butanoic acid
SMILES
CCCCS(=N)(=O)CCC(N)C(O)=O
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Buthionine Sulfoximine.Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Buthionine Sulfoximine.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Buthionine Sulfoximine.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Buthionine Sulfoximine.Approved, Investigational
DeslanosideDeslanoside may decrease the cardiotoxic activities of Buthionine Sulfoximine.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Buthionine Sulfoximine.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Buthionine Sulfoximine.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Buthionine Sulfoximine.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Buthionine Sulfoximine.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Buthionine Sulfoximine.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Buthionine Sulfoximine.Approved, Vet Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Buthionine Sulfoximine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentNeuroblastomas2
1WithdrawnTreatmentMelanoma (Skin)1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility2.2 mg/mLALOGPS
logP-2.9ALOGPS
logP-3ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)2.18ChemAxon
pKa (Strongest Basic)9.09ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area104.24 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity54.01 m3·mol-1ChemAxon
Polarizability23.65 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acids. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon).
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentAlpha amino acids
Alternative ParentsThia fatty acids / Carbo-azosulfones / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives / Carbonyl compounds
SubstituentsAlpha-amino acid / Thia fatty acid / Fatty acyl / Fatty acid / Carbo-azosulfone / Amino acid / Carboxylic acid / Monocarboxylic acid or derivatives / Organic nitrogen compound / Hydrocarbon derivative
Molecular FrameworkAliphatic acyclic compounds
External Descriptorsnon-proteinogenic alpha-amino acid, sulfoximide, homocysteines (CHEBI:28714 )
Drug created on October 20, 2016 18:54 / Updated on September 01, 2017 12:25